ÌÇÐÄÆƽâ°æ

In terms of revenue generated on the U.S. market, U.S. company AbbVie was, again, the leading pharmaceutical company in 2025. The company generated about ** billion dollars from pharmaceutical sales in the U.S. during that year.

U.S. market is key for Pfizer

Pharmaceutical firm Pfizer has seen its revenue in the United States decrease in 2023, mostly due to lower sales of its COVID-19 vaccine. Back in 2022, Pfizer generated worldwide revenues of over 100 billion U.S. dollars. The majority of Pfizer's revenue comes from the manufacture and sale of biopharmaceutical products. Prevnar 13 – a vaccine that helps protect against pneumococcal bacteria – is among the best-selling products in the company’s portfolio. 

Pfizer’s business segments

In 2019, Pfizer reorganized its operating structure into three business segments: biopharma, Upjohn, and consumer healthcare. But only one year later, the Upjohn business spun off and merged with Mylan to form a new company called Viatris. Thus, in fact, only the biopharma business remained, consisting of *** key therapeutic areas, including vaccines, oncology, and internal medicine. In the same year, Pfizer’s consumer healthcare business was merged with the respective business of GlaxoSmithKline (GSK). The new joint venture began operating globally as GSK Consumer Healthcare, which in 2022 became Haleon, a new, independent company.